DOCSLIB.ORG

Stoddard Solvent

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Stoddard Solvent DRAFT TOXICOLOGICAL PROFILE FOR STODDARD SOLVENT Prepared by: Clement International Corporation Under Contract No. 205-88-0608 Prepared for: U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Agency for Toxic Substances and Disease Registry May 1993 ***DRAFT FOR PUBLIC COMMENT*** DISCLAIMER The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry. ***DRAFT FOR PUBLIC COMMENT*** iii FOREWORD The Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99-499) amended the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA or Superfund). Section 211 of SARA also amended Title 10 of the U.S. Code, creating the Defense Environmental Restoration Program. Section 2704(a) of Title 10 of the U.S. Code directs the Secretary of Defense to notify the Secretary of Health and Human Services of not less than 25 of the most commonly found unregulated hazardous substances at defense facilities. Section 2704(b) of Title 10 of the U.S. Code directs the Administrator of the Agency for Toxic Substances and Disease Registry (ATSDR) to prepare a toxicological proflle for each substance on the list provided by the Secretary of Defense under subsection (b). Each profile must include the following: (A) The examination, summary, and interpretation of available toxicological information and epidemiological evaluations on a hazardous substance in order to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects. (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure which present a significant risk to human health of acute, subacute, and chronic health effects. (C) Where appropriate, identification of toxicological testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans. This toxicological profile is prepared in accordance with guidelines developed by ATSDR and EPA. The original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised and republished as necessary. The ATSDR toxicological profile is intended to characterize succinctly the toxicological and adverse health effects information for the hazardous substance being described. Each profile identifies and reviews the key literature (that has been peer-reviewed) that describes a hazardous substance's toxicological properties. Other pertinent literature is also presented but described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced. Each toxicological profile begins with a public health statement, which describes in nontechnical language a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health will be identified by ATSDR and the Environmental Protection Agency (EPA). The focus of the profiles is on health and toxicological information; therefore, we have included this information in the beginning of the document. IV Foreword The principal audiences for the toxicological profiles are health professionals at the Federal. state. and local levels, interested private sector organizations and groups, and members of the public. We plan to revise these documents in response to public comments and as additional data become available. Therefore. we encourage comments that will make the toxicological profile series of the greatest use. Comments should be sent to: Agency for Toxic Substances and Disease Registry Division of Toxicology Mail Stop E-29 Atlanta, Georgia 30333 This profile reflects our assessment of all relevant toxicological testing and information that has been peer reviewed. It has been reviewed by scientists from ATSDR, the Centers for Disease Control and Prevention (CDC). and other Federal agencies. It has also been reviewed by a panel of nongovernment peer reviewers and is being made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR. [Redacted] William L. Roper, M.D.. .H. Administrator Agency for Toxic Substances and Disease Registry v CONTENTS FOREWORD 0 0 0 0 0 o 0 0 0 0 0 0 0 0 o o o 0 0 0 0 • o • 0 0 0 0 o o o 0 0 0 0 0 o o 0 0 0 0 o o o 0 0 o o o o 0 o o o 0 0 0 o o 0 0 0 0 o o 0 iii LIST OF FIGURES 0 0 0 0 0 0 0 o o 0 0 0 0 0 0 o 0 o o 0 0 0 0 0 o o 0 0 0 0 0 0 o 0 0 0 0 o o o 0 0 o o o o 0 0 o o o o 0 0 o o o 0 0 o o o ix LIST OF TABLES 0 o o 0 0 0 0 0 • 0 o o o o 0 o 0 o o o o o o o 0 o o o o o o 0 0 o o o o 0 0 o o o 0 0 0 o o o 0 0 o o o 0 • 0 o 0 0 0 0 o o 0 xi 1. PUBLIC HEALTH STATEMENT 0 o o o o 0 0 0 0 o o o o 0 0 0 0 o o o o 0 0 o o o o o 0 o o o o 0 o o o o 0 0 o o o o o 0 o o o 1 1.1 WHAT IS STODDARD SOLVENT? o o 0 0 0 o o o o 0 0 0 0 0 o o 0 0 0 o o o o 0 o o o o 0 0 o o o o 0 0 o o o o 0 0 1 1.2 WHAT HAPPENS TO STODDARD SOLVENT WHEN IT ENTERS THE ENVIRONMENT? o o o o o o o 0 0 o o o o o o o 0 0 o o o o o 0 0 o o o o o 0 o o o o 0 0 o o o o 0 o o o o o o o o o o 0 o o o 1 1.3 HOW MIGHT I BE EXPOSED TO STODDARD SOLVENT? o o o 0 0 0 o o o o o o o o o o o o o o 0 o 2 1.4 HOW CAN STODDARD SOLVENT ENTER AND LEAVE MY BODY? o 0 o o o o o o o o o 0 o 2 1.5 HOW CAN STODDARD SOLVENT AFFECT MY HEALTH? o o 0 0 0 o o o 0 o o o o o 0 o o o o 0 o 3 1.6 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO STODDARD SOLVENT? 0 0 0 0 o 0 o 0 0 0 0 0 o o 0 0 0 0 o o o 0 0 o 0 o o o 0 0 o o o 0 o o o o o o o o o o o o o 3 1.7 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH? 0 o o o o 0 0 0 0 o o o 0 0 0 o o o 0 o o o o 0 o o o o 0 0 o o o o 0 o o o o 0 0 o o o 0 3 1.8 WHERE CAN I GET MORE INFORMATION? o o 0 o o o o 0 0 o o o o 0 0 o o o o o o •• o o o o o o ••• o 3 20 HEALTH EFFECTS o o 0 0 • o o o o 0 0 0 •• o o o 0 0 o o o 0 0 0 •• o 0 0 o o o o 0 • o o o 0 0 • o o o 0 •• o o 0 • o o 0 0 o o o 5 201 INTRODUCTION o o 0 0 0 0 0 0 o 0 0 0 0 0 0 o 0 0 0 0 0 • o 0 0 0 0 o o o 0 0 •• o o 0 0 o o o 0 0 0 • o 0 0 0 o o 0 0 0 • o 5 202 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE . o. o o o 0 •• o o 0 o o o 0 5 20201 Inhalation Exposure 0 0 0 0 0 0 0 0 0 0 0 0 0 •• 0 0 0 0 0 0 0 0 0 0 0 0 0 0 • 0 0 0 0 0 • 0 0 0 0 0 0 0 0 0 • 0 0 0 6 2020101 Death 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 • 0 0 0 0 0 0 0 0 0 ••• 0 • 0 • 0 0 0 • 0 0 0 0 0 0 0 0 6 20201.2 Systemic Effects 0 0 0 0 0 0 0 • 0 0 0 0 0 • 0 0 0 0 0 0 0 0 0 0 0 ••••• 0 0 0 0 0 • 0 0 0 • 0 0 0 0 14 20201.3 Immunological Effects 0 0 0 0 0 0 0 • 0 0 0 0 ••• 0 •• 0 0 0 0 • 0 0 0 ••• 0 0 • 0 0 0 • 0 0 0 20 20201.4 Neurological Effects 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 • 0 0 0 •••• 0 • 0 0 0 •• 0 0 • • • • • • 20 20201.5 Developmental Effects 0 0 0 0 0 0 0 0 0 0 0 •••• 0 0 0 0 0 0 •• 0 0 0 ••• 0 0 0 0 0 0 •• 0 0 21 20201.6 Reproductive Effects 0 0 0 0 0 0 0 0 0 0 0 0 0 0 • 0 0 0 0 •• o 0 0 0 • o o 0 • o o o 0 •• o 0 o o 22 20201.7 Genotoxic Effects 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 • 0 0 0 0 0 0 0 0 • 0 0 0 ••• 0 0 • 0 0 0 0 • 0 22 20201.8 Cancer 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 • 0 • 0 0 0 •••••• 0 0 •• 0 0 •••• 0 • • 22 20202 Oral Exposure 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 • 0 0 0 0 •• 0 0 0 0 0 0 0 0 •• 0 0 •• 0 0 0 0 0 0 22 2020201 Death 0 0 • 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 •• 0 0 0 0 0 0 0 0 0 0 0 0 0 ••• 0 0 0 0 0 0 0 ••• 0 0 • 0 • 23 2020202 Systemic Effects 0 0 • 0 0 0 0 0 • 0 0 0 0 0 0 0 0 0 0 0 0 0 0 •• 0 0 0 0 0 0 0 0 •• 0 0 0 0 0 0 0 • 0 23 2.20203 Immunological Effects 0 0 0 0 0 0 0 0 • 0 • 0 0 •• 0 0 0 • 0 0 0 ••• 0 0 •• 0 0 •• 0 0 0 • • • 23 20202.4 Neurological Effects 0 0 0 0 0 0 • 0 0 0 0 0 0 0 0 0 0 0 0 •• 0 0 ••• 0 0 0 0 0 0 ••• 0 • 0 0 0 0 23 2020205 Developmental Effects 0 0 0 0 0 0 0 0 0 0 0 0 • 0 0 •••• 0 0 • 0 0 0 •• 0 •••• 0 0 0 0 •• 0 23 2020206 Reproductive Effects 0 0 0 0 0 0 • 0 0 0 0 0 0 0 0 0 0 0 0 0 0 • 0 0 •• 0 0 0 0 0 0 0 • 0 0 0 • 0 0 23 2020207 Genotoxic Effects 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 • 0 0 0 0 • 0 0 0 0 0 0 0 0 •• 0 0 0 0 0 0 • 0 0 0 23 2020208 Cancer 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 •• 0 0 0 ••• 0 • 0 0 0 0 ••• 0 ••• 0 0 0 0 0 23 20203 Dermal Exposure 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 •• 0 0 0 0 0 ••••• 0 •• 0 0 0 ••• 0 • 0 23 2020301 Death 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 • 0 0 0 0 0 0 0 ••• 0 0 0 0 0 0 0 0 ••• 0 • 0 0 0 0 23 2020302 Systemic Effects 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 ••••• 0 • 0 0 0 0 ••• 0 • 0 23 2020303 Immunological Effects 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 •••• 0 •• 0 0 0 ••••• 0 • 0 0 0 0 • 23 20203.4 Neurological Effects 0 0 0 0 0 0 0 • o 0 0 0 o o o o 0 0 •• o o 0 •• o o o • o • o o 0 ••• o 0 0 • 24 2020305 Developmental Effects .
Load more

Recommended publications
  • Environmental Health Criteria 122 N-Hexane
    Environmental Health Criteria 122 n-Hexane Please note that the layout and pagination of this web version are not identical with the printed version. Hexane, n- (EHC 122, 1991) INTERNATIONAL PROGRAMME ON CHEMICAL SAFETY ENVIRONMENTAL HEALTH CRITERIA 122 n-HEXANE This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the United Nations Environment Programme, the International Labour Organisation, or the World Health Organization. Published under the joint sponsorship of the United Nations Environment Programme, the International Labour Organisation, and the World Health Organization First draft prepared by Dr. K. Chipman, University of Birmingham, United Kingdom World Health Orgnization Geneva, 1991 The International Programme on Chemical Safety (IPCS) is a joint venture of the United Nations Environment Programme, the International Labour Organisation, and the World Health Organization. The main objective of the IPCS is to carry out and disseminate evaluations of the effects of chemicals on human health and the quality of the environment. Supporting activities include the development of epidemiological, experimental laboratory, and risk-assessment methods that could produce internationally comparable results, and the development of manpower in the field of toxicology. Other activities carried out by the IPCS include the development of know-how for coping with chemical accidents, coordination of laboratory testing and epidemiological studies, and promotion of research on the mechanisms of the biological action of chemicals. WHO Library Cataloguing in Publication Data n-Hexane. (Environmental health criteria ; 122) Page 1 of 107 Hexane, n- (EHC 122, 1991) 1.Hexanes - adverse effects 2.Hexanes - toxicity I.Series ISBN 92 4 157122 5 (NLM Classification: QV 633) ISSN 0250-863X The World Health Organization welcomes requests for permission to reproduce or translate its publications, in part or in full.
    [Show full text]
  • Final Updated Petroleum Hydrocarbon Fraction Toxicity Values for the Vph
    FINAL UPDATED PETROLEUM HYDROCARBON FRACTION TOXICITY VALUES FOR THE VPH/EPH/APH METHODOLOGY Prepared for: Bureau of Waste Site Cleanup Massachusetts Department of Environmental Protection Boston, MA Prepared by: Office of Research and Standards Massachusetts Department of Environmental Protection Boston, MA November 2003 PREFACE In 1994 the Massachusetts Department of Environmental Protection (MA DEP) described a new approach for the evaluation of human health risks from ingestion exposures to complex petroleum hydrocarbon mixtures (MA DEP, 1994). The basis of the new approach was treating groups of compounds as if they had similar toxicities, in the absence of specific toxicity information on all the members of the group. The report included oral toxicity values for each of the designated petroleum hydrocarbon fractions. Since that time, there have been more recent efforts by others on this topic and additional information has become available to serve as a basis for updating the toxicity values. This document contains reviews of the more recent information, revisions to the oral toxicity values proposed in the 1994 report and new inhalation toxicity values. Readers will find different hydrocarbon compound size cutoffs for the hydrocarbon ranges identified here and in the 1994 report, compared to those in other related supporting documentation for this approach (i.e., the MA DEP VPH/EPH/APH analytical methods; guidance for Characterizing Risks Posed by Petroleum Contaminated Sites (MA DEP, 2002); risk spreadsheets for the MA DEP Bureau of Waste Site Cleanup). These differences relate primarily to subdivisions or truncation of ranges mandated by the analytical protocols employed for the analysis of the hydrocarbons (volatile (VPH), extractable (EPH) and air-phase(APH)) .
    [Show full text]
  • III IIII US005536880A United States Patent (19) 11 Patent Number: 5,536,880 Sugiya Et Al
    III IIII US005536880A United States Patent (19) 11 Patent Number: 5,536,880 Sugiya et al. 45) Date of Patent: Jul. 16, 1996 (54) MONOALKYLPHOSPHINE AND METHOD Primary Examiner-Paul J. Killos OF PRODUCING THE SAME Attorney, Agent, or Firm–Oblon, Spivak, McClelland, 75) Inventors: Masashi Sugiya; Seiji Shimura, both Maier & Neustadt of Tokyo, Japan 73) Assignee: Nippon Chemical Industrial Co., Ltd., (57) ABSTRACT Tokyo, Japan A monoalkylphosphine represented by the following for mula (1): (21) Appl. No.: 359,821 22 Filed: Dec. 20, 1994 (H, CH, gh (1) 30 Foreign Application Priority Data H CH,- CH-i-CH, (-CH H CH3 PH2 CH3 Dec. 24, 1993 (JP) Japan .................................... 5-329005 Dec. 24, 1993 (JP Japan .................................... 5-329006 wherein m indicates 1 or 2, and n indicates an integer of 0 (51) Int. Cl. ............................................. C07F 9/50 to 2. The monoalkylphosphine can effectively be obtained by reaction between phosphine and an alkene in the presence (52) U.S. Cl. ................................................................... 568/8 of an organic solvent and an anhydrous alkanesulfonic acid (58) Field of Search .................................................... 568/8 catalyst. 56) References Cited U.S. PATENT DOCUMENTS 5,354,918 10/1994 Ohsaki et al. .............................. 568/8 8 Claims, No Drawings 5,536,880 1. 2 MONOALKYLPHOSPHINE AND METHOD an intermediate of functional organic phosphorus com OF PRODUCING THE SAME pounds in consideration of the above-described facts, the inventors found a novel monoalkylphosphine compound. The inventors also found that a high yield of high-purity BACKGROUND OF THE INVENTION monoalkylphosphine can be obtained without dialkylphos 1. Field of the Invention phine and trialkylphosphine by reaction of phosphine and an The present invention relates to a novel monoalkylphos alkene in the presence of an organic solvent and anhydrous phine, and particularly, to a novel monoalkylphosphine alkanesulfonic acid as a catalyst.
    [Show full text]
  • WO 2012/110774 Al 23 August 2012 (23.08.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/110774 Al 23 August 2012 (23.08.2012) P O P C T (51) International Patent Classification: stitute of Pharmaceutical Sciences, 381 Royal Parade, C07D 239/42 (2006.01) A61K 31/506 (2006.01) Parkville, VIC 3052 (AU). GANAME, Danny [AU/AU]; C07D 401/12 (2006.01) A61P 35/00 (2006.01) WEHI Biotechnology Centre, 4 Research Avenue, Bun doora, VIC 3086 (AU). LESSENE, Romina [AU/AU]; (21) International Application Number: WEHI Biotechnology Centre, 4 Research Avenue, Bun PCT/GB20 12/000 176 doora, VIC 3086 (AU). (22) International Filing Date: (74) Agents: WATSON, Robert James et al; Mewburn Ellis 17 February 2012 (17.02.2012) LLP, 33 Gutter Lane, London EC2V 8AS (GB). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (30) Priority Data: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, 61/443,773 17 February 201 1 (17.02.201 1) US DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 61/523,489 15 August 201 1 (15.08.201 1) US HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, 61/579,729 23 December 201 1 (23. 12.201 1) u s KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (71) Applicant (for all designated States except US): CAN¬ MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, CER THERAPEUTICS CRC PTY LIMITED OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, [AU/AU]; 4 Research Avenu, Bundoora, VIC 3083 (AU).
    [Show full text]
  • Toxicological Profile for Stoddard Solvent
    TOXICOLOGICAL PROFILE FOR STODDARD SOLVENT U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Agency for Toxic Substances and Disease Registry June 1995 STODDARD SOLVENT ii DISCLAIMER The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry. STODDARD SOLVENT iii UPDATE STATEMENT A Toxicological Profile for Stoddard solvent was released on November 1993. This edition supersedes any previously released draft or final profile. Toxicological profiles are revised and republished as necessary, but no less than once every three years For information regarding the update status of previously released profiles, contact ATSDR at: Agency for Toxic Substances and Disease Registry Division of Toxicology/Toxicology Information Branch 1600 Clifton Road NE, E-29 Atlanta, Georgia 30333 STODDARD SOLVENT 1 1. PUBLIC HEALTH STATEMENT This Statement was prepared to give you information about Stoddard solvent and toemphasize the human health effects that may result from exposure to it. The Environmental Protection Agency (EPA) has identified 1,397 sites on its “National Priorities List” (NPL). Stoddard solvent has been found in at least seven of these sites. However, we do not know how many of the 1,397 NPL sites have been evaluated for Stoddard solvent. As EPA evaluates more sites, the number of sites at which Stoddard solvent is found may change. This information is important for you to know because Stoddard solvent may cause harmful health effects and because these sites are potential or actual sources of human exposure to Stoddard solvent. When a chemical is released from a large area, such as an industrial plant, or from a container, such as a drum or bottle, it enters the environment as a chemical emission.
    [Show full text]
  • TOXICOLOGICAL REVIEW of N-HEXANE (CAS No. 110-54-3)
    EPA/635/R-03/012 www.epa.gov/iris TOXICOLOGICAL REVIEW OF n-HEXANE (CAS No. 110-54-3) In Support of Summary Information on the Integrated Risk Information System (IRIS) November 2005 U.S. Environmental Protection Agency Washington, DC DISCLAIMER This document has been reviewed in accordance with United States Environmental Protection Agency policy and approved for publication. Mention of trade names or commercial products does not constitute endorsement or recommendation for use. ii CONTENTS—TOXICOLOGICAL REVIEW OF n-HEXANE (CAS No. 110-54-3) LIST OF TABLES AND FIGURES ...............................................v FOREWORD ............................................................... viii AUTHORS, CONTRIBUTORS, AND REVIEWERS ................................ ix 1. INTRODUCTION ..........................................................1 2. CHEMICAL AND PHYSICAL INFORMATION RELEVANT TO ASSESSMENTS .....3 3. TOXICOKINETICS RELEVANT TO ASSESSMENTS ............................4 3.1. ABSORPTION .....................................................4 3.2. DISTRIBUTION ....................................................5 3.3. METABOLISM .....................................................8 3.4. ELIMINATION ....................................................17 3.5. PHYSIOLOGICALLY BASED TOXICOKINETIC MODELS ...............21 4. HAZARD IDENTIFICATION................................................25 4.1. STUDIES IN HUMANS—EPIDEMIOLOGY AND CASE REPORTS ........25 4.1.1. Oral Exposure ..............................................25 4.1.2.
    [Show full text]
  • Trusted Results Suprasolv® High Purity Solvents for Gas Chromatography
    Trusted Results SupraSolv® High Purity Solvents for Gas Chromatography The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada. SupraSolv® and SupraSolv® hypergrade Solvents for gas chromatography As the world’s leading supplier of high-purity solvents, we offer a full range of products for every gas chromatography application in the laboratory - including highly sensitive pesticide and dioxin analyses. Our SupraSolv® and SupraSolv® hypergrade solvents are developed specifically for sensitive detection processes in residue and environmental analysis. They cover all areas of application, and provide the highest level of reliability for your analytical results. To ensure purity and suitability, we employ only the latest manufacturing processes. SupraSolv® solvents are recovered during special distillation cuts, and suitability testing involves a variety of detectors and highly concentrated solvents. As a result, these high-purity products support you in countless ways during your daily work - with individual specifications that are tailored to their specific area of application. SupraSolv® and SupraSolv® hypergrade solvents benefits • The most comprehensive application range due to the largest retention time range • Analytical reliability due to the highest possible purity and a minimal signal-to-noise ratio • Time and cost savings due to the best possible batch consistency, thus avoiding analysis repetition 2 Table of Contents SupraSolv® and SupraSolv® hypergrade Solvents for gas chromatography
    [Show full text]